Represents reimbursable costs pertaining to license agreements.

No definition available.

Name:	incy_LicenseAgreementReimbursableCosts
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents reimbursed costs pertaining to research and development expenses.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementResearchAndDevelopmentReimbursedCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the number of clinical-stage product candidates .

+ References

No definition available.

+ Details

Name:	incy_NumberOfProductCandidates
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Innovent (Details) - Innovent $ in Millions	1 Months Ended		3 Months Ended
	Jan. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) item	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
License agreements
Upfront and immediate milestone payment to be received under license agreement	$ 40.0
Research and development expenses reimbursed			$ 0.0
Reimbursable costs included in accounts receivable			$ 2.4	$ 1.2
Product candidates \| item		3
Development and Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		$ 104.0
Sales and Commercial Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		$ 202.5